source
- ai3Bio raises $48 million to develop T-helper cell-targeted immune-reset therapiesai3Bio, a new biotech startup formed from Corner Therapeutics and Novasenta, announced it has secured $48 million in an early-stage venture capital round. The company aims to create treatments for…
- Regulators Discuss Plans to Streamline Europe’s Drug Approval Process at 2026 RAPS ConvergenceA panel of European regulators gathered at the 2026 RAPS Convergence in Charlotte, North Carolina to discuss ongoing initiatives aimed at simplifying the continent’s regulatory framework. The offi…